You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

dMMR

Showing 1 - 25 of 169
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI, dMMR Colorectal Cancer Trial in Paris (Monalizumab/MEDI5257)

Not yet recruiting
  • MSI
  • dMMR Colorectal Cancer
  • Paris, France
    Department of medical oncology - Saint-Antoine Hospital
Nov 28, 2023

dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

Recruiting
  • dMMR Colorectal Cancer
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Apr 13, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

    Not yet recruiting
    • MSI-H/dMMR Gastroesophageal-junction Cancer
    • MSI-H/dMMR Gastric Cancer
    • (no location specified)
    Oct 30, 2023

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Colon Cancer Trial in Houston (Cemiplimab)

    Not yet recruiting
    • Colon Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2023

    Registry Study in MSI/dMMR Solid Tumors

    Not yet recruiting
    • DMMR Cancer
    • +2 more
      • (no location specified)
      Aug 21, 2023

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

      Recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • PD-1 inhibitor
      • Guangzhou, China
        Sun Yat-sen University Cancer Center
      Aug 9, 2023

      Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

      Not yet recruiting
      • Gastric
      • Colorectal Adenocarcinoma
      • Shenyang, Liaoning, China
        Liaoning Cancer Hospital & Institute
      Nov 1, 2023

      Colorectal Cancer Trial (Pembrolizumab)

      Recruiting
      • Colorectal Cancer
      • Amsterdam, Netherlands
        Netherlands Cancer Institute
      Jan 3, 2023

      Cancer of Rectum Trial (Nivolumab, Ipilimumab)

      Not yet recruiting
      • Cancer of Rectum
      • (no location specified)
      Feb 7, 2023

      Neoadjuvant Envafolimab in Resectable and Locally Advanced

      Not yet recruiting
      • Locally Advanced Rectal Carcinoma
      • MSI-High
      • (no location specified)
      Dec 9, 2022

      Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

      Not yet recruiting
      • Colonic Neoplasms
      • Dostarlimab
      • +2 more
      • (no location specified)
      May 3, 2023

      DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

      Not yet recruiting
      • Endometrial Cancer
      • (no location specified)
      Feb 14, 2023

      MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

      Not yet recruiting
      • MSI-H Colorectal Cancer
      • +3 more
      • (no location specified)
      Apr 23, 2023

      Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

      Not yet recruiting
      • Multiple Cancer
      • Colorectal Cancer
      • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
      • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
      • (no location specified)
      Aug 20, 2023

      MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

      Terminated
      • MSI-H/dMMR Solid Tumor
      • Guangzhou, Guangdong, China
        Sun Yat-Sen University Cancer Center
      Oct 17, 2022

      Tumors, Rectal Trial (Dostarlimab)

      Not yet recruiting
      • Neoplasms, Rectal
      • Dostarlimab
      • (no location specified)
      Feb 2, 2023

      Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

      Recruiting
      • Colorectal Carcinoma
      • Guangzhou, China
        Sun Yat-sen University
      Dec 29, 2022

      Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

      Recruiting
      • Rectal Neoplasms
      • Cleveland, Ohio
        Cleveland Clinic, Case Comprehensive Cancer Center
      Jan 25, 2023

      Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

      Not yet recruiting
      • Colorectal Cancer Stage IV
      • +2 more
      • (no location specified)
      Jun 19, 2022

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

      Recruiting
      • Colorectal Cancer
      • +3 more
      • Neoadjuvant therapy with PD-L1 inhibitor
      • Guangzhou, Guangdong, China
        the Third Affiliated Hospital of Sun Yat-Sen University
      May 10, 2022

      Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

      Terminated
      Has Results
      • Locally Advanced Malignant Solid Neoplasm
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 22, 2022

      Localized Resectable Tumor, MSI/dMMR or EBV-positive Gastric Cancers Trial in France (Pembrolizumab)

      Recruiting
      • Localized Resectable Tumor
      • MSI/dMMR or EBV-positive Gastric Cancers
      • Lyon, France
      • +6 more
      Apr 28, 2022